Niacinamide Market Size & Share, By Form (Powder, Liquid, Granules), By Application (Cosmetics & Personal Care [Skincare, Haircare], Pharmaceuticals, Food & Beverages) - Global Supply & Demand Analysis, Growth Forecasts, Statistical Report 2025-2034

Niacinamide Market - Regional Analysis

APAC Market Insights

Asia Pacific in the niacinamide market is expected to be the dominant region, with the highest share of 45.2% by the end of 2034. The aspects of K-beauty influence, administrative reforms, epidemic in diabetes, and the aging population are major key drivers that are uplifting the overall market in the region. For instance, the presence of 145 million diabetic patients in China is fueling the pharmaceutical demand. Meanwhile, the PLI scheme in India has readily incentivized domestic API manufacturing, while South Korea’s USD 15.8 billion cosmetics export market is driving the demand for niacinamide serum, thus suitable for bolstering market exposure in the overall region.

The market in China is readily dominating the overall region, with an expected market share of 28.5% during the forecast period. This is effectively attributed to a surge in skincare demand as well as an increase in pharmaceutical API manufacturing. Besides, the country also accounts for 62% of the international niacinamide API outcome, leading to supply to the majority of markets, such as the U.S. and Europe. In addition, administrative spending has upsurged by 18.5% as of 2023 to cater to pellagra in rural locations and aid more than 1.8 million patients every year, thus creating an optimistic outlook for the market.

The niacinamide market in India is expected to grow at a rate of 8.2% during the projected timeline, which is highly driven by cost-effective skincare and generic drug production facilities. Besides, the government has made an allocation of USD 2.3 billion as of 2023, catering to over 21.5% growth over 10 years, to aid at least 2.8 million dermatology and diabetic patients. Meanwhile, the push for public health, development in OTC skincare, and success in the PLI scheme are critical developments that are fueling the market growth in the country.

North America Market Insights

North America in the niacinamide market is anticipated to be the fastest-growing region and grab an estimated 30.5% of the international market share by the end of 2034, along with a 7.8% growth rate, which is readily attributed to pharmaceutical and skincare demand. The U.S. is readily dominating the region, with a surge in regional sales, as well as Medicaid and Medicare coverage extension. Meanwhile, Canada is also witnessing an escalated integration across public health programs. Besides, administrative alignment, preventive healthcare, and clinical dermatology are other notable trends that are uplifting the overall market in the region.

The niacinamide market in the U.S. is expected to account for USD 3.9 billion in niacinamide sales as of 2024, with skincare catering to 45% and diabetes medications, constituting 30%, thereby resulting in the increasing demand. The existence of AHRQ studies, an upsurge in skincare, as well as Medicare expenditure, are other critical developments that are fueling the market demand in the region. For instance, there has been a surge in Medicare expenditure to USD 805 million, which is an increase of 18% over 5 years, for metabolic-based treatments. Meanwhile, there has been a 28% YoY upsurge in serums, along with 11.5% of niacinamide considered as the standard product in the country.

The market in Canada is also significantly growing at 7.3%, with an expected USD 485 million revenue by the end of 2034. The market’s upliftment in the country is centered on the basis of indigenous health, generic dominance, and public health incorporation. For instance, Ontario readily covers niacinamide for more than 200,500 diabetic patients every year. Besides, through generic dominance, there has been the availability of 48.5% of cheap products in comparison to branded alternative options. Meanwhile, an estimated 21.5% of the budget has increase for home-based accessibility to B3 therapies, thus suitable for market upliftment in the country.

North America Niacinamide trade and supply chain facilities (2022-2025) with verified government/industry sources:

Sources: FDA, Health Canada, U.S. ITC, HHS, CIHI

Europe Market Insights

Europe in the niacinamide market is anticipated to hold a considerable share of 20.3% during the forecasted timeline, accounting for a valuation of €8.4 billion, with Germany catering 35.7%, France with 25.6%, and the UK with 20.6%. Besides, diabetes management, the existence of Europe health reforms, innovation in skincare, and aging demographics are other notable drivers uplifting the overall market in the region. For instance, almost 37% of the population in Germany is more than 60 years of age, and effectively utilizes niacinamide for metabolic health. Besides, brands in France, such as La Roche-Posay, effectively fuel 32.5% of premium serum sales, while health policies in the region have allocated €2.9 billion for boosting the market.

The market in Germany is deliberately dominating the region’s market share with 35.6% by the end of the forecast period, which is attributed to the existence of skincare industries and strong pharmaceutical infrastructure. Besides, the country increasingly manufactures almost 46% of the region’s niacinamide APIs, with the majority of centers in Leipzig and Frankfurt. Meanwhile, there has been an increase in the government expenditure, which has currently reached €4.1 billion as of 2024, further prioritizing dermatological and metabolic applications, thus suitable for market development in the country.

The niacinamide industry in France is expected to capture an estimated 25.9% of the region’s market share during the projected period, which is highly driven by government-based research and development, along with the existence of luxury skincare preferences. Besides, the country has generously made a provision of approximately 7.3% of its overall healthcare budget, accounting for € 1.5 billion as of 2023, for niacinamide, of which 32% has been allocated for premium serums comprising the ingredient. Meanwhile, K-beauty partnerships and collaborations, tax incentives, and cosmetics dominance are other key developments that are suitable for uplifting the market in the country.

Europe-based Government Funding for Niacinamide (2022-2025)

Source: Ministère de la Santé, HAS, AIFA, Ministero della Salute, AEMPS, Junta de Andalucía